摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Benzyl-1-methyl-2,4-dioxo1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-hydroxy-benzylamide | 449209-89-6

中文名称
——
中文别名
——
英文名称
3-Benzyl-1-methyl-2,4-dioxo1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-hydroxy-benzylamide
英文别名
3-benzyl-N-[(4-hydroxyphenyl)methyl]-1-methyl-2,4-dioxoquinazoline-6-carboxamide
3-Benzyl-1-methyl-2,4-dioxo1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-hydroxy-benzylamide化学式
CAS
449209-89-6
化学式
C24H21N3O4
mdl
——
分子量
415.448
InChiKey
RQKIQASKKKQQAF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    90
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-methoxybenzylamide 、 三溴化硼 、 、 碳酸氢钠二氯甲烷 、 crude product 、 methanol diethyl ether 作用下, 以 二氯甲烷 为溶剂, 反应 0.5h, 以provides 1.35 g (yield: 74%) of the desired compound的产率得到3-Benzyl-1-methyl-2,4-dioxo1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-hydroxy-benzylamide
    参考文献:
    名称:
    Quinazolines as MMP-13 inhibitors
    摘要:
    从式(I)中选择的一种化合物:其中:R1代表从氢,氨基,烷基,烯基,氨基烷基,芳基,芳基烷基,杂环和环烷基烷基中选择的基团,可选地取代,W代表氧,硫或═N—R′,其中R′如描述中所定义,X1,X2和X3代表氮或—C—R6,其中R6如描述中所定义,Y代表氧,硫,—NH或—N(C1-C6)烷基,Z代表氧,硫,—NR7,其中R7如描述中所定义,和59可选的碳原子,n是1到8的整数,包括Z1代表—CR8R9,其中R8和R9如描述中所定义,A代表芳香或非芳香,杂环或非杂环环系,m是0到7的整数,基团R2如描述中所定义,R3代表氢,烷基,烯基,炔基或式2中的基团:其中Z2,B,R5,P和q如描述中所定义,可选地,它们的外消旋体、异构体、N-氧化物和药学上可接受的盐,以及含有它们的药物制剂,可用作13型基质金属蛋白酶的特异性抑制剂。
    公开号:
    US20020193377A1
点击查看最新优质反应信息

文献信息

  • QUINAZOLINES AS MMP-13 INHIBITORS
    申请人:Warner-Lambert Company LLC
    公开号:EP1368324A1
    公开(公告)日:2003-12-10
  • [EN] QUINAZOLINES AS MMP-13 INHIBITORS<br/>[FR] QUINAZOLINES UTILISEES COMME INHIBITEURS DE LA MMP-13
    申请人:WARNER LAMBERT CO
    公开号:WO2002064572A1
    公开(公告)日:2002-08-22
    A compound selected from those of formula (I): in which: R1 represents a group selected from hydrogen, amino, alkyl, alkenyl, aminoalkyl, aryl, arylalkyl, heterocycle, and cycloalkylalkyl, optionally substituted, W represents oxygen, sulphur, or =N-R', in which R' is as defined in the description, X1, X2 and X3 represent nitrogen or -C-R6 in which R6 is as defined in the description, Y represents oxygen, sulphur, -NH, or -N(C1-C6)alkyl, Z represents oxygen, sulphur, -NR7 in which R7 is as defined in the description, and optionally carbon atom, n is an integer from 1 to 8 inclusive, Z1 represents -CR8R9 wherein R8 and R9 are as defined in the description, A represents aromatic or non-aromatic, heterocyclic or non-heterocyclic ring system, m is an integer from 0 to 7 inclusive, the group(s) R2 is (are) is as defined in the description, R3 represents hydrogen, alkyl, alkenyl, alkynyl, or a group of formula: in which Z2, B, R5, P and q are as defined in the description, optionally, the racemic forms thereof, isomers thereof, N-oxydes thereof, and the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.
查看更多